Stock Ratings / Health Care / GLUE / options

MGTX (27) PRME (21) ODTX (59) CGEM (36) ⌘ Pro Terminal →

Monte Rosa Therapeutics Inc. (GLUE) Options Positioning, Max Pain & Unusual Sweeps

$10.87 +0.18% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Monte Rosa Therapeutics Inc. (GLUE) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $927.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GLUE)Realized 20D OHLCV Swing Band: ±12.1%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.1%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (GLUE)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for GLUE.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GLUE)

✓Walkthrough of GLUE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GLUE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -43.24%⚡ TESTING RESISTANCE

2026-10-30O $10.85H $11.13L $10.45C $10.87VOL 1.35M

RES: $11.07SUP: $7.43SMA50: $12.08SMA200: $17.38

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GLUE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GLUE Butterfly Map → + Track GLUE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GLUE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GLUE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GLUE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GLUE)

Health Care Rank #863 of 1016 ⚔️ MGTX vs GLUE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GLUE vs. MGTX, PRME, ODTX, CGEM)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Monte Rosa Therapeutics Inc. (GLUE) ranks #863 by composite RQD confidence (33/100, grade E) and #372 by equity capitalization ($927.4M). Within this direct 5-issuer industry benchmark cohort, GLUE leads on earnings valuation at N/A trailing P/E, while GLUE leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with GLUE at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GLUE ACTIVE Monte Rosa Therapeutics Inc.	E	33/100	—	—	-35.0%	+0.18%	$927.4M	Benchmark Subject
MGTX MeiraGTx Holdings plc	E	27/100	—	—	-35.0%	-0.46%	$932.1M	/mgtx-vs-glue →
PRME Prime Medicine Inc.	E	21/100	—	—	-35.0%	-2.24%	$950.4M	/prme-vs-glue →
ODTX Odyssey Therapeutics Inc.	C-	59/100	—	—	—	+1.48%	$953.0M	/odtx-vs-glue →
CGEM Cullinan Therapeutics Inc.	D-	36/100	—	—	-35.0%	-0.71%	$994.3M	/cgem-vs-glue →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001826457

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Monte Rosa Therapeutics Inc. (GLUE) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$38.6M, operating cash flow of -$22.8M, and free cash flow of -$27.5M (-172.3% YoY). On the balance sheet, GLUE closed FY2025 with $448.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$38.6M	-$22.8M	-$27.5M	$448.7M	—
FY2024 (FY)	2024-12-31	$0	-$72.7M	$42.0M	$38.0M	$438.7M	—
FY2023 (FY)	2023-12-31	$0	-$135.4M	-$43.8M	-$43.8M	—	—

3. GLUE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GLUE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $10.87 (+0.18% 1D, market cap $927.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GLUE ranks #863 in composite RQD confidence.

How does GLUE compare to MGTX and PRME in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), GLUE carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MGTX (MeiraGTx Holdings plc) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $932.1M) and PRME (Prime Medicine Inc.) posts a E grade (21/100 RQD, P/E N/A, ROIC -35.0%, cap $950.4M). Among the 5-stock peer group, GLUE leads on earnings multiple (N/A) while GLUE leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GLUE?

Per GLUE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001826457), Monte Rosa Therapeutics Inc. generated $0 in revenue, -$38.6M in net income, and -$27.5M in free cash flow against $448.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GLUE trading relative to its 50-day, 200-day, and 52-week technical levels?

GLUE last traded at $10.87 (+0.18% on volume of 1,307,295 shares), positioning the stock -10.02% below its 50-day simple moving average ($12.08) and -37.46% below its 200-day simple moving average ($17.38). Across its 52-week range of $9.68 to $25.77, GLUE sits at the 7.4% percentile with a 14-day RSI of 44.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.1% ($9.55 to $12.19).

GLUE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is GLUE's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for GLUE.

Direct Sub-Reports: GLUE RQD Cockpit GLUE 12M Forecast GLUE Earnings & Move GLUE Dividends & DRIP GLUE Insiders & 13F GLUE Whale Options GLUE Profit Sankey GLUE News & Why